Clinical Trials Directory

Trials / Completed

CompletedNCT01444404

A Study of AMG 820 in Subjects With Advanced Solid Tumors

A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics of AMG 820 in Adult Subjects With Advanced Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
25 (actual)
Sponsor
AmMax Bio, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.

Conditions

Interventions

TypeNameDescription
DRUGAMG 820AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.

Timeline

Start date
2008-03-31
Primary completion
2014-02-06
Completion
2014-02-06
First posted
2011-09-30
Last updated
2023-01-19

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01444404. Inclusion in this directory is not an endorsement.